PASIPHAE

PASIPHAE (NCT03322215) is an academic randomized phase 2 trial comparing palbocilib and fulvestrant versus capecitabine in patients with advanced breast cancer that have progressed to previous endocrine therapy with an aromatase inhibitor. Study PI is Theodoros Foukakis and in total 50 patients were included.

Metastatic core biopsies have been collected at study enrollment.